“Generic drug-making is a fast-track business”: Sandoz trademark head reveals approach to IP management
In a wide-ranging interview, INTA’s president-elect and global head of trademarks for Sandoz, David Lossignol, talks about the challenges of managing pharmaceutical brand rights and the growing threat of IP restrictions.
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the WTR experts.